Trial Profile

Evaluation of the immunogenicity of pneumococcal conjugate vaccine [pneumococcal 7-valent CRM197 vaccine conjugate] and routine pediatric immunizations in HIV-infected children treated with highly active antiretroviral therapy (HAART)

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; DTaP vaccine; Hepatitis B vaccine recombinant; Measles mumps and rubella virus vaccine; Pneumococcal vaccine
Indications Diphtheria; Hepatitis B; Measles; Pertussis; Pneumococcal infections; Rubella; Tetanus
Focus Pharmacodynamics

26 Nov 2013 Biomarkers information updated
11 Aug 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com